Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2022, Vol. 36 ›› Issue (5): 106-112.doi: 10.6040/j.issn.1673-3770.0.2021.374

Previous Articles    

Research progress of anlotinib combination therapy in cancer treatment

SONG Qing1,2,3Overview,SONG Xicheng2,3,4Guidance   

  1. 1. Department of Weifang Medical University, Clinical Medical College, Weifang 261032, Shandong, China;
    2. Department of Otorhinolaryngology & Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, Shandong, China;
    3. Department of Otorhinolaryngology Laboratory, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, Shandong, China;
    4. Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai 264000, Shandong, China
  • Published:2022-09-20

Abstract: Anlotinib is a multi-targeting tyrosine kinase inhibitor that can play an anti-tumor role by regulating angiogenesis in cancer or an immunosuppressive microenvironment. Anlotinib shows therapeutic effects in patients with advanced or recurrent cancer and has been approved for the clinical treatment of non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer, medullary thyroid cancer, and other types of tumors. Clinical studies have found that anlotinib combined with chemotherapy, radiotherapy, and immune-checkpoint inhibitors could inhibit tumor growth and showed significantly better therapeutic effects than anlotinib monotherapy. In this article, we review the mechanism of action of anlotinib and the progress in research on anlotinib in combination with other cancer treatments.

Key words: Anlotinib, Combination medication, Cancer treatment, Antiangiogenesis, Immune microenvironment

CLC Number: 

  • R73
[1] Shen GS, Zheng FC, Ren DF, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol, 2018, 11(1): 120. doi:10.1186/s13045-018-0664-7.
[2] Xie CY, Wan XZ, Quan HT, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J]. Cancer Sci, 2018, 109(4): 1207-1219. doi:10.1111/cas.13536.
[3] Tiseo M, Franciosi V, Ardizzoni A. Multi-target inhibitors in non-small cell lung cancer(NSCLC)[J]. Ann Oncol, 2006, 17(Suppl 2): ii55-ii57. doi:10.1093/annonc/mdj924.
[4] Takahashi S. Vascular endothelial growth factor(VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy[J]. Biol Pharm Bull, 2011, 34(12): 1785-1788. doi:10.1248/bpb.34.1785.
[5] Song F, Hu B, Cheng JW, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma[J]. Cell Death Dis, 2020, 11(7): 573. doi:10.1038/s41419-020-02749-7.
[6] Tang XL, Zheng Y, Jiao DM, et al. Anlotinib inhibits cell proliferation, migration and invasion via suppression of c-met pathway and activation of ERK1/2 pathway in H446 cells[J]. Anticancer Agents Med Chem, 2021, 21(6): 747-755. doi:10.2174/1871520620666200718235748.
[7] Lin BY, Song XM, Yang DW, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene, 2018, 654: 77-86. doi:10.1016/j.gene.2018.02.026.
[8] Yang Q, Ni LC, Imani S, et al. Anlotinib suppresses colorectal cancer proliferation and angiogenesis via inhibition of AKT/ERK signaling cascade[J]. Cancer Manag Res, 2020, 12: 4937-4948. doi:10.2147/CMAR.S252181.
[9] Qin TT, Liu ZJ, Wang J, et al. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling[J]. Cancer Biol Med, 2020, 17(3): 753-767. doi:10.20892/j.issn.2095-3941.2020.0024.
[10] Liang HG, Wang MZ. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer[J]. Cancer Manag Res, 2019, 11: 7707-7719. doi:10.2147/CMAR.S212238.
[11] Liu SC, Qin TT, Liu ZJ, et al. Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells[J]. Cell Death Dis, 2020, 11(5): 309. doi:10.1038/s41419-020-2511-3.
[12] Shi JZ, Zhang YJ, Wang JZ, et al. Anlotinib combined with chemoradiotherapy exhibits significant therapeutic efficacy in esophageal squamous cell carcinoma[J]. Front Oncol, 2020, 10: 995. doi:10.3389/fonc.2020.00995.
[13] Yang YL, Li L, Jiang ZS, et al. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer[J]. Cancer Immunol Immunother, 2020, 69(12): 2523-2532. doi:10.1007/s00262-020-02641-5.
[14] Liu YC, Wu L, Tong RZ, et al. PD-1/PD-L1 inhibitors in cervical cancer[J]. Front Pharmacol, 2019, 10: 65. doi:10.3389/fphar.2019.00065.
[15] Deng ZM, Liao W, Wei W, et al. Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe[J]. Cancer Cell Int, 2021, 21(1): 37. doi:10.1186/s12935-020-01721-x.
[16] Gao Q, Jiang YQ, Li XJ, et al. Intratumoral injection of anlotinib hydrogel combined with radiotherapy reduces hypoxia in lewis lung carcinoma xenografts: assessment by micro fluorine-18-fluoromisonidazole positron emission tomography/computed tomography hypoxia imaging[J]. Front Oncol, 2021, 11: 628895. doi:10.3389/fonc.2021.628895.
[17] Guo L, Zhang LY, Guan Y, et al. In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy[J]. Thorac Cancer, 2021, 12(5): 593-602. doi:10.1111/1759-7714.13780.
[18] Wang GY, Sun MX, Jiang YF, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma[J]. Int J Cancer, 2019, 145(4): 979-993. doi:10.1002/ijc.32180.
[19] Zhao D, Xie B, Yang Y, et al. Progress in immunotherapy for small cell lung cancer[J]. World J Clin Oncol, 2020, 11(6): 370-377. doi:10.5306/wjco.v11.i6.370.
[20] 陈曦, 乔明哲. 免疫检查点抑制剂在复发或转移性头颈鳞癌的治疗进展[J]. 山东大学耳鼻喉眼学报, 2019, 33(3): 42-48. doi: 10.6040/j.issn.1673-3770.1.2019.001. CHEN Xi, QIAO Mingzhe. Progress of immune checkpoint inhibitors in the treatment of recurrent or metastatic head and neck squamous cell carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(3): 42-48. doi: 10.6040/j.issn.1673-3770.1.2019.001.
[21] Li T, Qian YX, Zhang CF, et al. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo[J]. Transl Lung Cancer Res, 2021, 10(4): 1873-1888. doi:10.21037/tlcr-21-192.
[22] Liu JY, Fan ZF, Li S, et al. Target therapy for metastatic alveolar soft part sarcoma: a retrospective study with 47 cases[J]. Ann Transl Med, 2020, 8(22): 1493. doi:10.21037/atm-20-6377.
[23] Long ZY, Lu YJ, Li MH, et al. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review[J]. Ann Palliat Med, 2021, 10(6): 7073-7082. doi:10.21037/apm-20-1790.
[24] Han BH, Li K, Wang QM, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11): 1569-1575. doi:10.1001/jamaoncol.2018.3039.
[25] Zhou AP, Bai YX, Song Y, et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial[J]. Oncologist, 2019, 24(8): e702-e708. doi:10.1634/theoncologist.2018-0839.
[26] He ZL, Liu J, Ma YW, et al. Anlotinib combined with cranial radiotherapy for non-small cell lung cancer patients with brain metastasis: a retrospectively, control study[J]. Cancer Manag Res, 2021, 13: 6101-6111. doi:10.2147/CMAR.S319650.
[27] Zhu X, Tao H, Kong C, et al. 1386P Anlotinib combined with whole brain radiation therapy(WBRT)for advanced non-small cell lung cancer with multiple brain metastases: an open-label, single-arm phase II trial[J]. Ann Oncol, 2020, 31: S881. doi:10.1016/j.annonc.2020.08.1700.
[28] Kong C, Zhu X, Jiang M, et al. Anlotinib in combination with whole brain radiotherapy for advanced non-small-cell lung cancer with brain metastases progressive or developed after at least one lines of prior treatment[J]. Int J Radiat Oncol, 2021, 111(3): e569. doi:10.1016/j.ijrobp.2021.07.1537.
[29] Chai PW, Zhou CD, Jia RB, et al. Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report[J]. Diagn Pathol, 2020, 15(1): 2. doi:10.1186/s13000-019-0922-1.
[30] Jang HS, Woo SR, Song KH, et al. API5 induces cisplatin resistance through FGFR signaling in human cancer cells[J]. Exp Mol Med, 2017, 49(9): e374. doi:10.1038/emm.2017.130.
[31] Sugimoto K, Miyata Y, Nakayama T, et al. Fibroblast Growth Factor-2 facilitates the growth and chemo-resistance of leukemia cells in the bone marrow by modulating osteoblast functions[J]. Sci Rep, 2016, 6: 30779. doi:10.1038/srep30779.
[32] Gao Y, Liu PF, Shi RH. Anlotinib as a molecular targeted therapy for tumors[J]. Oncol Lett, 2020, 20(2): 1001-1014. doi:10.3892/ol.2020.11685.
[33] Wang HY, Chu JF, Zhang P, et al. Safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in Chinese patients with advanced/metastatic soft tissue sarcoma[J]. Onco Targets Ther, 2020, 13: 1561-1568. doi:10.2147/OTT.S235349.
[34] Ni J, Cheng XZ, Chen J, et al. Anlotinib as exploratory therapy for platinum-resistant ovarian cancer: a retrospective study on efficacy and safety[J]. Onco Targets Ther, 2020, 13: 9857-9863. doi:10.2147/OTT.S268613.
[35] Wang HY, Chu JF, Zhao Y, et al. A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer[J]. Cancer Manag Res, 2020, 12: 3827-3834. doi:10.2147/CMAR.S249678.
[36] Chu TQ, Zhong RB, Zhong H, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC[J]. J Thorac Oncol, 2021, 16(4): 643-652. doi:10.1016/j.jtho.2020.11.026.
[37] Yang SJ, Zhang WJ, Chen Q, et al. Clinical investigation of the efficacy and safety of anlotinib with immunotherapy in advanced non-small cell lung cancer as third-line therapy: a retrospective study[J]. Cancer Manag Res, 2020, 12: 10333-10340. doi:10.2147/CMAR.S280096.
[38] Chen Y, Yang ZY, Wang YN, et al. Pembrolizumab plus chemotherapy or anlotinib vs. pembrolizumab alone in patients with previously treated EGFR-mutant NSCLC[J]. Front Oncol, 2021, 11: 671228. doi:10.3389/fonc.2021.671228.
[39] Yuan M, Fang JM, Zhu ZZ, et al. The clinical activity and safety of anlotinib combined with anti-PD-1 antibodies in patients with advanced solid tumors[J]. J Clin Oncol, 2020, 38(15_suppl): e15081. doi:10.1200/jco.2020.38.15_suppl.e15081.
[40] Wang YN, Zhang QN, Miao LY, et al. Nivolumab in combination with anlotinib achieved remarkable efficacy in a patient with driver-negative lung squamous cell carcinoma and PS of 4[J]. Ann Palliat Med, 2020, 9(6): 4384-4388. doi:10.21037/apm-20-2096.
[41] Jiang M, Zhang XC. Antiangiogenesis combined with immunotherapy to treat advanced small-cell carcinoma of the esophagus resistant to chemotherapy: according to the guidance of next-generation sequencing[J]. Onco Targets Ther, 2021, 14: 1613-1621. doi:10.2147/OTT.S293733.
[42] She L, Su L, Shen LF, et al. Retrospective study of the safety and efficacy of anlotinib combined with dose-dense temozolomide in patients with recurrent glioblastoma[J]. Front Oncol, 2021, 11: 687564. doi:10.3389/fonc.2021.687564.
[43] Zhai CY, Zhang XL, Ren LL, et al. The efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer[J]. Front Oncol, 2020, 10: 619010. doi:10.3389/fonc.2020.619010.
[1] LI Jingjing, WU Xinxin, MAO Ning, ZHENG Guibin, MU Yakui, CHU Tongpeng, JIA Chuanliang, ZHENG Haitao, MI Jia, SONG Xicheng. CT-based radiomics nomogram for the preoperative prediction of central lymph node metastases of papillary thyroid carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(4): 51-59.
[2] The objective of this study was to analyze the effects and possible regulatory mechanisms that Notch receptors could have on cisplatin resistance, observed in nasopharyngeal carcinoma. MethodsWestern blot analysis was used for the detection of Notch receptor expression in nasopharyngeal carcinoma cells and cisplatin-resistant nasopharyngeal carcinoma cells(5-8F, 5-8F/CDDP). Flow cytometry was used to investigate how the combined treatment with 10 μM CDDP and different concentrations of γ-secretase inhibitor(DAPT)could affect apoptosis in 5-8F/CDDP cells. Flow cytometry was also used for the detection of cell cycle stages in DAPT-treated 5-8F / CDDP cells. Finally, western blotting was also used for the detection of drug resistance-related protein expression. All experiments were followed by statistical data analysis. ResultsWe observed significantly higher Notch1 and Notch4 receptor expression in 5-8F/CDDP cells than in 5-8F cells(P=0.003, P=0.004). Furthermore, we described that Notch signaling was inhibited by DAPT in 5-8F/CDDP cells, followed by a significant increase in the apoptosis rate and decrease in cell proliferation, induced by cisplatin in a dose-dependent manner(P<0.05). Moreover, after inhibiting the Notch signaling pathway in 5-8F/CDDP cells, DAPT treatment significantly decreased the expression of Cyclin E and CDK-2, proteins involved in cell cycle regulation, and contributed to blocking the cells in the G1/S phase(P<0.05). At the same time, the expression levels of both the EMT-related protein Slug and the DNA excision repair protein ERCC1 significantly decreased, while that of E-Cadherin was up-regulated. ConclusionUp-regulated expression of Notch1 and Notch4 receptors is associated with cisplatin resistance in nasopharyngeal carcinoma cells. The inactivation of the Notch signaling pathway might thus have the potential to enhance the efficiency of cisplatin chemotherapy in drug-resistant nasopharyngeal carcinoma cells by inhibiting EMT rather than blocking the G1/S cell cycle phase.. Cisplatin resistance in nasopharyngeal carcinoma cells is affected by Notch receptors through the regulation of epithelial-mesenchymal transition rather than cell cycle controlHAN Jibo, ZOU You, YANG Rui, TAO Zezhang Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, ChinaAbstract:Objective〓 [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 105-110.
[3] This study aimed to describe the clinical features of 74 patients with cleft palate cysts and fistulas and analyze the diagnosis and treatment methods. MethodsBetween January 2010 and September 2019, the clinical data of 74 patients with branchial cleft cysts and fistulas were retrospectively reviewed and analyzed with related literature in our department. ResultsOf the 74 patients, 50 patients were diagnosed with second branchial cleft anomalies, 13 patients had first branchial cleft lesions, 10 patients had third branchial cleft lesions, and one patient had a fourth branchial cleft lesion. All patients received surgical treatment. After the exclusion of 3 patients who were lost to follow-up, 67 patients were successfully treated, 3 patients reported relapse, and 1 had permanent facial paralysis. ConclusionsThe clinical manifestations of congenital cleft palate cysts and fistulas are diverse, and the differential diagnosis is complicated. It is essential to perform a detailed physical examination and preoperative evaluation to make an accurate diagnosis. The approach for management is individualized, and surgical rehabilitation is the preferred treatment.. Clinical analysis of 74 cases of branchial cleft cysts and fistulasWANG Yingying, ZHANG Liqing, ZHOU Han, DONG Shikun, CHEN Haibing, CHEN Xi, DONG Weida Department of Otorhinolaryngology, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu, ChinaAbstract:Objective〓 [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 111-116.
[4] ObjectiveThe aim of this study was to provide new perspectives and targets for the treatment of HNSCC by screening differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma(HNSCC)using bioinformatics. MethodsThe chip dataset, GSE109756, was downloaded from the GEO database, and the online analysis tool, GEO2R, was used to screen differentially expressed genes in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The DAVID 6.8 and STRING online software were used to analyze the function of the differentially expressed genes, their pathway enrichment, and their protein interactions. Cytoscape was used to visualize and analyze the protein interactions. The online analysis tool, X2K, was used to find the transcription factors, the kinases of differentially expressed genes, and their mutual regulatory relationship with the targeted genes. ResultsNinety-one differentially expressed genes, including 50 up-regulated and 41 down-regulated genes(P<0.05; | logFC | > 1), were found in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The GO and KEGG pathway analyses suggested that these differentially expressed genes were mainly enriched with immunomodulation, extracellular matrix, and other processes. Through the construction of a protein-protein interaction network, we screened CD163, VSIG4, and 3 other core differentially expressed genes(P<0.05), which were up-regulated after cetuximab treatment. In addition, our analysis shows that transcription factors, including SUZ12, TP63, and ESR1, played a key role in cetuximab treatment(P<0.05)and MAPK14, CDK1, and MAPK1 were the most important kinases during the process(P<0.05). ConclusionCD163, VSIG4, and the aforementioned transcription factors and protein kinases may be involved in the biological processes that underlie cetuximab treatment of HNSCC. This study provides new perspectives to facilitate further understanding of the biological mechanism that underlies cetuximab treatment of HNSCC and the exploration of the effectiveness of HNSCC treatment.. Analysis of differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma using bioinformaticsYU Kena1, SUN Kaiyue2, ZHANG Jie1, JIN Peng1 1. Department of Otorhinolaryngology & Head and Neck Surgery, The Second Hospital of Shandong University, Jinan 250033, Shandong, China; 2. Shandong Provincial Otorhinolaryngology Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, Shandong, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 117-124.
[5] PAN Xinliang. Improving the standard treatments for thyroid nodules and malignant tumors [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 1-12.
[6] SONG Xicheng, ZHENG Haitao. A review of autofluorescence imaging of the parathyroid gland [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 19-25.
[7] QING Xiaoyan, XU YiquanOverview, LI ChaoGuidance. Advances in molecular mechanisms of anaplastic thyroid cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 26-31.
[8] WU Xinxin, LI Jingjing, MAO Ning, ZHENG Guibin, ZHENG Haitao, CUI Jingjing, JIA Chuanliang, CHU Tongpeng, MOU Yakui, SONG Xicheng. A radiomics nomogram based on computed tomography for predicting benign and malignant thyroid nodules [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 32-39.
[9] CHEN Haibing, WEI Ya'nan, XU Xiaoquan, CHEN Xi. Prediction of cervical lymph node metastasis in papillary thyroid cancer based on XGBoost artificial intelligence and enhanced computed tomography [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 40-45.
[10] DENG Di, LIU Jun, LI Linke, WANG Ji, LIU Jifeng, LV Dan, WANG Haiyang, GAN Weigang, WANG Jun, LI Bo, CHEN Fei. Two-stage reconstructive strategy using a flap for non-circumferential tracheal defects [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 52-57.
[11] ZHENG Guibin, ZHANG Guojun, MA Chi, WEI Shujian, SUN Haiqing, WU Guochang, GUO Yawen, ZHENG Haitao, SONG Xicheng. The safety and feasibility of transoral endoscopic thyroidectomy vestibular approach(TOETVA)in papillary thyroid cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 58-63.
[12] FANG Zhongju, ZHANG Yongxia, ZHAO Jiandong, ZONG Liang, ZHAI Xingyou, LI Xinjian, PENG Xin, REN Nan, CHEN Liwei, LIU Mingbo. Combined treatment of chylous leakage after lymph node dissection for thyroid cancer [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 64-68.
[13] HUANG Naisi, MA Ben, GUAN Qing, WANG Yunjun, WEI Wenjun, LU Zhongwu, YANG Shuwen, XU Weibo, XIANG Jun, JI Qinghai, WANG Yu. Lateral neck lymph node mapping in thyroid cancer surgery [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 69-74.
[14] WANG Jiashuo, GUO Xing, YAN Aihui. Giant cyst formation from lymph node metastasis in papillary thyroid cancer: a case study [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 111-113.
[15] WANG Maolin, LI Julan, XIAN Kunlun. Efficacy of different transplantation schemes for parathyroid gland resection in patients with secondary hyperparathyroidism [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(3): 114-119.
Full text



No Suggested Reading articles found!